Search research articles
Contact Us
Filters
Showing results (191-200 of 248) with videos related to
Page
of 25
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 1999
Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis
P J Hesketh, R J Gralla, R T Webb, et al.
Clinical Lung Cancer
|
December 5, 2003
Unfavorable therapeutic index of cisplatin/gemcitabine/vinorelbine in advanced non-small-cell lung cancer
Paul J Hesketh, Christopher J Nauman, Ann M Hesketh, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 4, 2016
SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay
Primo N Lara, James Moon, Paul J Hesketh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 1, 1995
Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen
P J Hesketh, T Beck, M Uhlenhopp, et al.
Bone Marrow Transplantation
|
January 10, 2002
Prospective evaluation of antiemetic outcome following high-dose chemotherapy with hematopoietic stem cell support
K K Ballen, A M Hesketh, C Heyes, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
March 1, 1996
Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide
P J Hesketh, D R Gandara, A M Hesketh, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 6, 2011
Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial
Randeep Sangha, Angela M Davies, Primo N Lara, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 3, 2007
Phase II study of gemcitabine and cisplatin in patients with previously untreated extensive stage small cell lung cancer: Southwest Oncology Group Study 9718
Paul J Hesketh, Kari Chansky, Valerie Israel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 1989
GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis
P J Hesketh, W K Murphy, E P Lester, et al.
Molecular Metabolism
|
July 1, 2024
Skeletal muscle BMAL1 is necessary for transcriptional adaptation of local and peripheral tissues in response to endurance exercise training
Mark R Viggars, Hannah E Berko, Stuart J Hesketh, et al.
Page
of 25
Search research articles
Search
Showing results (191-200 of 248) with videos related to
Sort By:
Page
of 25
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 1999
Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis
P J Hesketh, R J Gralla, R T Webb, et al.
Clinical Lung Cancer
|
December 5, 2003
Unfavorable therapeutic index of cisplatin/gemcitabine/vinorelbine in advanced non-small-cell lung cancer
Paul J Hesketh, Christopher J Nauman, Ann M Hesketh, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 4, 2016
SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay
Primo N Lara, James Moon, Paul J Hesketh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 1, 1995
Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen
P J Hesketh, T Beck, M Uhlenhopp, et al.
Bone Marrow Transplantation
|
January 10, 2002
Prospective evaluation of antiemetic outcome following high-dose chemotherapy with hematopoietic stem cell support
K K Ballen, A M Hesketh, C Heyes, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
March 1, 1996
Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide
P J Hesketh, D R Gandara, A M Hesketh, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 6, 2011
Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial
Randeep Sangha, Angela M Davies, Primo N Lara, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 3, 2007
Phase II study of gemcitabine and cisplatin in patients with previously untreated extensive stage small cell lung cancer: Southwest Oncology Group Study 9718
Paul J Hesketh, Kari Chansky, Valerie Israel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 1989
GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis
P J Hesketh, W K Murphy, E P Lester, et al.
Molecular Metabolism
|
July 1, 2024
Skeletal muscle BMAL1 is necessary for transcriptional adaptation of local and peripheral tissues in response to endurance exercise training
Mark R Viggars, Hannah E Berko, Stuart J Hesketh, et al.
Page
of 25